G Model

ARTICLE IN PRESS

JVAC-15631; No. of Pages 2

Vaccine xxx (2014) xxx–xxx

Contents lists available at ScienceDirect

Vaccine journal homepage: www.elsevier.com/locate/vaccine

Letter to the Editor Pneumococcal vaccination in people living with HIV

a r t i c l e

i n f o

Keywords: HIV Invasive Pneumococcal Disease Pneumococcal vaccination

a b s t r a c t Streptococcus pneumoniae is the leading bacterial opportunistic infection (OI) in HIV positive individuals. Anti-retroviral treatment (ART) reduces their risk of Invasive Pneumococcal Disease (IPD), however, it remains 20- to 40-fold greater than that of the general population. In HIV-infected adults, pneumococcal vaccination (PCV) induces more durable and functional antibody responses in individuals on ART at the time of vaccination than in ART-naive adults, independently of the baseline CD4+ cell count. National guidelines in the UK recommend vaccination in HIV-infected adults with CD4 count >200 cells/mL and advise that it be considered for those with CD4 count 200 cells/mL and advise that it be considered for those with CD4 count